June 5, 2020 / 10:57 AM / 2 months ago

BRIEF-FDA Approves Merck’s Recarbrio For Treatment Of Adults With Hospital-Acquired Pneumonia

June 5 (Reuters) - Merck & Co Inc:

* FDA APPROVES MERCK’S RECARBRIO™ (IMIPENEM, CILASTATIN, AND RELEBACTAM) FOR THE TREATMENT OF ADULTS WITH HOSPITAL-ACQUIRED AND VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (HABP/VABP) Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below